With AstraZeneca’s COVID-19 vaccine having lost much of its relevance and the company hinting a week ago that it might get out of the vaccine business altogether, CEO...

The Bill & Melinda Gates Foundation is bankrolling Celanese’s work to develop a refillable long-acting implant for delivery of a contraceptive drug, committing $6...

Novartis is already suing a long list of generics producers that aim to bring copycats of the company's popular heart failure drug Entresto to market. Now, the Swiss ...

Even as Novartis charts a course to convert Sandoz into a standalone generics juggernaut in Europe, long-standing pressure on the copycat drug industry is forcing the...

Checkpoint Therapeutics announced the discontinuation of its CONTERNO cancer trial last week, citing the war in Ukraine as a leading reason. The phase 3 study is a gl...

Roche and its U.S. subsidiary Genentech have signed an exclusive worldwide license agreement with Shanghai-based Jemincare for the development and commercialization o...

Rare disease specialist Aeglea BioTherapeutics has announced both a leadership transition and corporate restructuring, with the goal of focusing resources on its clin...

Before settling on a $5.4 billion price tag for Global Blood Therapeutics, Pfizer had to fight off a mysterious “Company A.” Now, the identity of that contender has b...

Bavarian Nordic has been scrambling to ramp up the supply of the only approved monkeypox vaccine, Jynneos, to meet growing global demand. The Danish company’s latest ...

Gravity Branding chose a positive outlook when it named Novartis’ latest FDA approved drug Vijoice but also set a deeper meaning. Vijoice “can be regarded as o...